Frost became the CEO and chairman of OPKO Health, Inc. upon the consummation of the merger of Acuity Pharmaceuticals Inc., Froptix Corporation and eXegenics, Inc., on March 27, 2007. He was named chairman of the board of Ladenburg Thalmann Financial Services, an investment banking, asset management, and securities brokerage firm, providing services through its principal operating subsidiary, Ladenburg Thalmann & Co. Inc., in July 2006; and has been a Director of Ladenburg Thalmann, since March 2005. Frost also serves as chairman of the board of Directors of PROLOR Biotech, Inc. (NYSE Amex: PBTH), a development stage biopharmaceutical company.
ncG1vNJzZmivp6x7qrDOpaWerKekv7W0jZympmegnbatuMipZJ%2Bqn6jBbrrErWSwp6KptW6BkGtsbg%3D%3D